Loading...
•
Sep 30, 2022
Reviva Q3 2022 Earnings Report
Reported third quarter results and recent business highlights.
Key Takeaways
Reviva Pharmaceuticals reported a net loss of $3.5 million for the third quarter of 2022. As of September 30, 2022, the Company’s cash totaled approximately $23.2 million.
Over 30% enrollment in ongoing global, pivotal Phase 3 RECOVER trial
Topline data for Phase 3 RECOVER trial evaluating brilaroxazine for schizophrenia still expected mid-2023
Cash totaled $23.2M Million as of September 30, 2022
Announced $8.5 million registered direct offering and concurrent private placement in September 2022
Forward Guidance
Reviva anticipates several milestones and events, including enrollment initiation at sites in India for the RECOVER Phase 3 study expected in Q4 2022 and topline data for the pivotal Phase 3 trial evaluating brilaroxazine for the treatment of schizophrenia anticipated in mid-2023.
Positive Outlook
- Enrollment initiation at sites in India for RECOVER Phase 3 study expected in Q4 2022
- Topline data for pivotal Phase 3 trial evaluating brilaroxazine for the treatment of schizophrenia anticipated in mid-2023
- May initiate Phase 2a studies in bipolar disorder, MDD, ADHD, PAH and IPF subject to the receipt of non-dilutive financing in 2023
- Pursuing strategic partnership opportunities for the development of our pipeline
- Evaluating grant and other non-dilutive financing opportunities for product candidates from Federal and State Healthcare Agencies and Foundations
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...